Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

Inclusion Criteria: * Participants who are medically healthy with no clinically significant or relevant abnormalities as determined by medical history, physical or neurological examination, vital signs, 12-lead ECG, screening clinical laboratory profiles (hematology, biochemistry, coagulation, and urinalysis), as deemed by the Investigator or designee. * Body weight of at minimum 50 kg and body mass index (BMI) within the range 18 to 32 kg/m\^2 (inclusive) at the Screening. * Male and female participants should adhere to the protocol defined contraceptive methods. Exclusion Criteria: * History or presence of medical (eg, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological or other disorders) or psychiatric conditions or diseases. * History of clinically significant hypersensitivity or idiosyncratic reaction to the study drugs or related compounds. * History of drug or alcohol abuse within 2 years prior to first dosing * Current tobacco users or smokers (defined as any tobacco or nicotine-containing product use within 3 months prior to first dosing). * Donation of whole blood from 3 months prior to first dose administration, or of plasma from 30 days before first dose administration. * Female participants who have a positive pregnancy test at Screening or Day -1, or who are lactating. * Positive drugs of abuse, cotinine, or alcohol screen at Screening or Day -1.